ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/dLFC3dW4Tv https://t.co/LNCUIQjnGf

• https://bit.ly/39m9Vxm

Can You Reduce Frequency of Methotrexate Monitoring? https://t.co/TnXZVCTv10 https://t.co/4q8sWwQ5aC

• https://bit.ly/3M8PXEG

Wiki Guidelines Approach to Pyogenic Osteomyelitis https://t.co/PaYolXmPv3 https://t.co/AXrwhRjQs4

• https://bit.ly/3MhrwVG

Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis This study identified genetic risk variants from genome-wide association analysis of OA patients to calculate PRSs associated with subsequent need for joint replacement surgery. https://t.co/ZhAiuFu8iw https://t.co/OsR6p9m2S9

• https://bit.ly/3LcY5D1

Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/qdC8VXC1ko https://t.co/C67sB6IFVL

• https://bit.ly/3PmojGo

NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/I88bvuU4cg https://t.co/4xNH0IZnGA

• https://bit.ly/3wb1opN

Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/FJjDxm7wfQ https://t.co/EiuSGaXgeh

• https://bit.ly/38mGpYe

Acne with JAK Inhibitors JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi. https://t.co/ADzaBjgsAN https://t.co/Yydo47UGYl

• https://bit.ly/3N7gemM

Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA. https://t.co/LFfZAFgMWE https://t.co/n8X45pInYQ

• https://bit.ly/3yuXY2S

Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth

• https://bit.ly/3w8E1xh

2019 Gabapentin Rx=69 million; 7th most common Rx in USA. MMWR: 62,652 overdose deaths, 52% had Pos. gabapentin test. OD deaths w/ GAB involved usually involved illicitly manufactured fentanyls. GAB+Opioids=BAD COMBO! https://t.co/qQbPmwzAgJ

• https://bit.ly/3laKKjG

EADV Dermatology Meeting presents data on the 2 year safety of Deucravacitinib, (TYK2 inhibitor); also showing DEUC is effective in scalp, nail, & palmoplantar PSO. Data from the phase 3 POETYK PSO-1 and PSO-2 trials https://t.co/cFz6XkpA69 https://t.co/ZNJzph6i5N https://t.co/QJZEhzqkY4

• https://bit.ly/3whEDAR
• https://bit.ly/3w9DOtN

Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA. https://t.co/spcdweO0pE https://t.co/0stEBPy6hc

• https://bit.ly/3PegvWZ